Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human
Infections
Respiratory Tract Infections
Virus Diseases
Infection Viral

Interventions

BIOLOGICAL: Low dose A/H2N3c + standard dose MF59
BIOLOGICAL: Intermediate dose A/H2N3c + standard dose MF59
BIOLOGICAL: High dose A/H2N3c + standard dose MF59
BIOLOGICAL: High dose A/H2N3c non-adjuvanted
BIOLOGICAL: Lowest dose A/H2N3c + high dose MF59
BIOLOGICAL: Low dose A/H2N3c + high dose MF59

Sponsor

Seqirus

Collaborators

[object Object]